D. E. Shaw & Co., Inc. Nektar Therapeutics Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Nektar Therapeutics stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 2,548,990 shares of NKTR stock, worth $3.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,548,990

Previous 4,098,844 37.81%

Holding current value

$3.16 Million

Previous $2.3 Million 3.27%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $759,428 - $1.49 Million	-1,549,854 Reduced 37.81%	2,548,990 $2.37 Million
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $850,155 - $1.15 Million	-2,024,180 Reduced 33.06%	4,098,844 $2.3 Million
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $1.54 Million - $3.18 Million	-3,029,297 Reduced 33.1%	6,123,024 $3.67 Million
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $3.1 Million - $6.03 Million	5,850,660 Added 177.2%	9,152,321 $5.31 Million
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $1.39 Million - $6.85 Million	2,173,745 Added 192.72%	3,301,661 $2.31 Million

Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $911,459 - $1.92 Million	448,995 Added 66.13%	1,127,916 $2.55 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $389,013 - $657,740	127,965 Added 23.23%	678,921 $2.17 Million
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $287,398 - $559,384	-90,662 Reduced 14.13%	550,956 $2.09 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $1.06 Million - $3.49 Million	254,385 Added 65.69%	641,618 $3.46 Million
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $305,037 - $518,536	-28,166 Reduced 6.78%	387,233 $5.23 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $1.17 Million - $1.69 Million	89,514 Added 27.47%	415,399 $7.46 Million
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $1.47 Million - $1.82 Million	-89,026 Reduced 21.46%	325,885 $5.59 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $9.47 Million - $14.6 Million	-572,103 Reduced 57.96%	414,911 $8.3 Million
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $7.04 Million - $8.49 Million	446,395 Added 82.57%	987,014 $16.8 Million
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $288,533 - $431,147	17,392 Added 3.32%	540,619 $8.97 Million
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $8.56 Million - $11.9 Million	507,590 Added 3246.08%	523,227 $12.1 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $1.16 Million - $2.23 Million	-79,932 Reduced 83.64%	15,637 $279,000
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $371,596 - $541,354	-23,415 Reduced 19.68%	95,569 $2.06 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $3.66 Million - $7.85 Million	-216,435 Reduced 64.53%	118,984 $2.17 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $27.2 Million - $31.9 Million	-877,802 Reduced 72.35%	335,419 $11.9 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $13.4 Million - $19.6 Million	423,588 Added 53.64%	1,213,221 $40.8 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $19 Million - $35.4 Million	625,430 Added 380.89%	789,633 $26 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $8.98 Million - $13.2 Million	-193,286 Reduced 54.07%	164,203 $10 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $17.2 Million - $38.9 Million	-372,678 Reduced 51.04%	357,489 $17.5 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $41.7 Million - $78.8 Million	726,274 Added 18655.9%	730,167 $77.6 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $408,581 - $1.07 Million	-17,749 Reduced 82.01%	3,893 $232,000
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $385,011 - $519,408	21,642	21,642 $519,000

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account